ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 6th 2024ARVO
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
ARVO 2024: Understanding the reading problem for patients with central vision loss
May 5th 2024ARVO
Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Vision-related activity difficulties in people diagnosed with nAMD and vision impairment
May 5th 2024ARVO
Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.
3 companies announce their plans for data presentations at ARVO 2024
April 24th 2024ARVO
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.
COPHy 2024: Should all patients with idiopathic intracranial hypertension have a lumbar puncture?
March 16th 2024COPHy
Andrew G. Lee, MD, outlines his stance on whether all patients with idiopathic intracranial hypertension should have a lumbar puncture, emphasizing clinical judgment and treatment strategies.
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024COPHy
The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.
EnVision Summit 2024: Using the miCOR 700 device for phacoemulsification cataract surgery
February 21st 2024EnVision Summit
Anthony Mai, MD, shared results from using the miCOR 700 device, which is a new device from Zeiss, for phacoemulsification cataract surgery at the EnVision Summit 2024. He spoke with Peg Achenbach, OD, FAAO, Executive Director/Global Ambassador Strategies, Ophthalmology and Optometry at MJH Life sciences, on location in Puerto Rico to share more about his presentation.
EnVision Summit 2024: Leadership talk guides women in eye care through personal IPO journey
February 16th 2024EnVision Summit
Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.